News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sonora Medical Systems Announces a Major Ultrasound Probe Study



11/4/2008 10:15:09 AM

FARMINGDALE, N.Y., Nov. 4 /PRNewswire-FirstCall/ -- Misonix, Inc. , today announced that its Sonora Medical Systems subsidiary ("Sonora Medical"), a leading supplier of after market products, services and test equipment to the medical imaging market, presented an ultrasound probe study in Sweden at the country's annual clinical engineering meeting recently held in Goteborg, Sweden. The paper was presented by the School for Technology and Health, the Royal Technical University, the Biomedical Engineering Department of Karolinska University Hospital and the Department for Clinical Physiology of Karolinska University Hospital and was titled "Defective ultrasound transducers in Swedish hospitals." The presentation from this study can be downloaded at www.4sonora.com.

Using the Sonora FirstCall probe testing system the authors tested 704 probes in clinical use from 30 hospitals representing 7 ultrasound manufacturers. The authors found that 39.8% of the transducers tested had functional failures and that there was no statistical difference in the number of probe failures discovered on systems under service contract or not on service contract. The study also reported that "small" probe errors which do not appear to affect B-mode image quality can result in large measuring errors in spectral and color Doppler. Among the conclusions presented was "tests of transducers on a regular basis is, in our opinion, a necessity in order to minimize the risk that defective transducers are in use in our hospitals."

Commenting on this study, G. Wayne Moore, President and CEO of Sonora Medical Systems, said, "We have long known that as few as two dead elements in a transducer can materially impact the spectral Doppler in terms of both spectral broadening and mean velocity errors. Previously published studies on transducers in clinical use have shown 25 to 30 percent have undiagnosed functional failures. The Swedish study underscores the need to test transducers on a regular basis to insure the clinical efficacy of the ultrasound examination, as well as the safety of the patient. The FirstCall transducer tester has become a standard in hospitals around the world in insuring the proper functionality of these ultrasound transducers. In fact, Sweden has more First Calls per capita than any other country and requires First Call testing of probes prior to their use."

Michael A. McManus, Jr., President and CEO of Misonix, said, "We are very pleased to see that more of the international community is recognizing the issues related to functional failures in transducers and the importance in regular testing with our proprietary First Call product."

About Sonora Medical Systems, Inc.

Sonora Medical's Test Instrument Division designs and develops a wide range of ultrasound test equipment for Original Equipment Manufacturers as well as hospital physicists, clinical and biomedical engineers. Sonora Medical continues to expand its ultrasound metrology product offerings and is the world leader in providing these devices and acoustic measurement services.

About Misonix:

Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Misonix has a minority equity position in Focus Surgery, Inc., which uses high intensity focused ultrasound technology in prostate procedures. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

CONTACT: Richard Zaremba of Misonix, +1-631-694-9555, invest@misonix.com,
or Investor Relations, Kevin McGrath of Cameron Associates, Inc.,
+1-212-245-4577, Kevin@cameronassoc.com

Web site: http://www.4sonora.com/
http://www.misonix.com/


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES